Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Transient receptor potential cation channel subfamily M member 6 (TRPM6)
- Target
- TRPM6
- Molecular classification
- Ion channel (specifically, transient receptor potential cation channel), Enzyme (serine/threonine kinase domain, bifunctional channel-kinase)
01
Overview
Transient receptor potential cation channel subfamily M member 6 (TRPM6) is an ion channel protein essential for the transport of magnesium ions into epithelial cells, predominantly in the intestine and kidney. It plays a key role in systemic magnesium homeostasis, influencing cellular processes such as energy production, protein synthesis, and parathyroid hormone regulation. TRPM6 is a bifunctional protein containing both ion channel and serine/threonine kinase domains. Mutations causing loss of TRPM6 function result in hypomagnesemia with secondary hypocalcemia, characterized by neurological and muscular symptoms beginning in infancy[1][2][3][4].
- Other names
- TRPM6 kinaseTRPM6, cleaved formCHAK2FLJ22628Channel kinase 2Melastatin-related TRP cation channel 6HMGXHOMGHOMG1HSH
02
Mechanism of action
Clinical action is via magnesium supplementation to restore normal ion levels. TRPM6 itself is a channel for magnesium influx; pharmacological modulation in research might focus on controlling channel activity[2].
03
Biological functions
Magnesium and calcium ion transport and homeostasisSignal transduction (by altering membrane potential or intracellular ion concentrations)Regulation of parathyroid hormone production and blood calcium levelsCell growth and death processes, protein synthesis, maintenance of nucleotides
04
Disease associations
Hypomagnesemia with secondary hypocalcemia (defective TRPM6 results in magnesium and calcium deficiency, leading to seizures and muscle spasms in infancy)Possible roles in other magnesium-related disorders
05
Safety considerations
No specific safety concerns for targeting TRPM6 pharmacologically, but dysfunction in TRPM6 leads to neurological symptoms, hypomagnesemia, and hypocalcemia, which can be life-threatening if untreated[2]
06
Interacting drugs
No clinically approved drugs directly target TRPM6. Magnesium supplementation is used for conditions caused by TRPM6 dysfunction
07
Biomarkers
Low serum magnesium (Mg²⁺) and calcium (Ca²⁺) levels are biomarkers for TRPM6 dysfunction and associated diseases, particularly hypomagnesemia with secondary hypocalcemia
Beyond the preview
Go deeper on Transient receptor potential cation channel subfamily M member 6 (TRPM6).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Transient receptor potential cation channel subfamily M member 6 (TRPM6).